Dramatic effect of @entity4677 on @entity302 negative XXXX .

@entity1 @entity4677 @entity1625 @entity410 @entity2045 @entity1092 @entity109 @entity302
OBJECTIVE: To investigate the properties of @entity4677 in a @entity1 with severe @entity302 negative @entity2045 . Treatment of @entity302 negative @entity2045 relies on the drugs that are effective in @entity1625 , but it is usually pharmacoresistant. @entity4677 is a new antiepileptic drug with a broad-spectrum activity that includes efficacy against positive @entity2045 . CASE REPORT: This @entity1 had had @entity302 falls since the age of 2 years. In 2000, she was on @entity109 (100 mg/day) and @entity1092 (2000 mg/day) and had two drop attacks per month. Clinical examination showed negative @entity2045 of the arms clearly predominating on the left side, which was confirmed by a polygraphic EEG. @entity4677 (1000 mg/day in the first week, increased to 2000 mg/day thereafter) was added. During the first 2 months, the @entity1 experienced four minor @entity410 without fall. A polygraphic EEG confirmed that the @entity1 's @entity302 negative @entity2045 disappeared during @entity4677 treatment. At 1-year follow-up, this @entity1 had had only one @entity410 . CONCLUSIONS: The result of @entity4677 treatment in this @entity1 is encouraging, but efficacy should be confirmed in larger series. A long-term follow-up is also necessary to establish that this antimyoclonic effect of @entity4677 is maintained over a period of years.
